Gilead Sciences, Inc.

Pliant Therapeutics, Inc.

Gilead Pharmasset LLC

Terns, Inc.

Terns Pharmaceuticals, Inc.

Randall Halcomb

John O Link

Manoj C Desai

Winston C Tse

Paul A Roethle

Thorsten A Kirschberg

Qi Liu

Michael Graupe

Scott D Schroeder

Michael L Mitchell

Hong Yang

Lianhong Xu

Hongtao Liu

Hongyan Guo

Ryan McFadden

James G Taylor

Eda Y Canales

Paul Hrvatin

Scott E Lazerwith

Jennifer R Zhang

Elizabeth M Bacon

Darryl Kato

Jianyu Sun

Randall W Vivian

James D Trenkle

Richard L Mackman

William John Watkins

Choung U Kim

Jeromy J Cottell

Aesop Cho

F Anthony Romero

Hon Chung Hui

Jay P Parrish

Yunfeng Eric Hu

Joseph H Saugier

Yingzi Xu

Hyung-Jung Pyun

Evan S Krygowski

Hui Li

David John Morgans, Jr

Lan Jiang

Gustave Bergnes

Jacob Cha

Timothy Hom

Gediminas J Brizgys

Carina E Cannizzaro

Steven S Bondy

Chien-Hung Chou

Kerim Babaoglu

Roland D Saito

Kyla Bjornson

Chien-hung Chou

Chun Chen

John R Somoza

Richard Y Huang

Lee Shun Chong

Xiaowu Chen

Xiaochun Han

Brandon Heath Brown

Richard Hung Chiu Yu

Yafan Lu

Yingmei Qi

Jessica Jade Chao

Hyung-Jun Pyun

Brian Gallagher

Jake Cha

Erwina Rudio

Darin Allen

Ryan Mc Fadden

Provided herein are compounds, preferably (R)-N-(4-(chlorodifluoromethoxy) phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide having the Formula I or a pharmaceutically acceptable salt or tautomer thereof, that inhibits tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Amino acid compounds and methods of use

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Thyroid hormone receptor beta agonist compounds

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity

The invention relates to compounds of formula (I): or a salt thereof, wherein R, A, L, and Rand n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;1 integrin inhibitors that are useful for treating tissue specific fibrosis.

N-acyl amino acid compounds and methods of use

The invention relates to compounds of formula (I): or a salt thereof, wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Modulators of toll-like receptors

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus. 

Compounds for the treatment of HIV

Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.

Tricyclic ASK1 inhibitors

Provided herein are compounds of formula (I) or formula (Ia) that inhibit tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. 

Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R, R, R, R, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are &#x3b1;v&#x3b2;6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). 

Growing community of inventors

Foster City, CA, United States of America

Randall Halcomb